Augmentation of radiation response by motesanib, a multikinase inhibitor that targets vascular endothelial growth factor receptors.
about
Targeted treatment of differentiated and medullary thyroid cancer.Phase 1 trial of bevacizumab with concurrent chemoradiation therapy for squamous cell carcinoma of the head and neck with exploratory functional imaging of tumor hypoxia, proliferation, and perfusionLimited Tumor Tissue Drug Penetration Contributes to Primary Resistance against Angiogenesis InhibitorsMotesanib and advanced NSCLC: experiences and expectations.Primary frontal sinus squamous cell carcinoma in three dogs treated with piroxicam combined with carboplatin or toceranib.
P2860
Augmentation of radiation response by motesanib, a multikinase inhibitor that targets vascular endothelial growth factor receptors.
description
2010 nî lūn-bûn
@nan
2010 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Augmentation of radiation resp ...... elial growth factor receptors.
@ast
Augmentation of radiation resp ...... elial growth factor receptors.
@en
type
label
Augmentation of radiation resp ...... elial growth factor receptors.
@ast
Augmentation of radiation resp ...... elial growth factor receptors.
@en
prefLabel
Augmentation of radiation resp ...... elial growth factor receptors.
@ast
Augmentation of radiation resp ...... elial growth factor receptors.
@en
P2093
P2860
P1476
Augmentation of radiation resp ...... elial growth factor receptors.
@en
P2093
Albert J van der Kogel
Angela Coxon
Anthony Polverino
Deric L Wheeler
Eric A Armstrong
Kevin R Kozak
Paul M Harari
Tim J Kruser
P2860
P304
P356
10.1158/1078-0432.CCR-09-3385
P407
P577
2010-05-27T00:00:00Z